SCYNEXIS, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on November 10, 2021, by SCYNEXIS, Inc. (SCYX), reports the announcement of financial results for the third quarter ended September 30, 2021. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the attached press release (Exhibit 99.1) referenced in Item 2.02 but are not included in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. Investors must refer to the attached press release for comparative financial data.
Guidance, Outlook, and Management Commentary
Management scheduled a conference call for November 10, 2021, at 8:30 a.m. Eastern Time to review the financial results. The filing notes that the information in Item 2.02 and the attached exhibit is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2021 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the conference call.
- Confirm the date and time of the earnings conference call (November 10, 2021, 8:30 a.m. ET).